Echinacea / IL1β Cancer Research Results

Ech, Echinacea: Click to Expand ⟱
Features: Immune system
Echinacea may have immune-modulating properties, which could theoretically help the body fight cancer.

Echinacea — Echinacea is a heterogeneous botanical preparation derived mainly from Echinacea purpurea, Echinacea angustifolia, and/or Echinacea pallida, containing alkylamides, caffeic acid derivatives such as cichoric acid, polysaccharides, glycoproteins, flavonoids, and other phenolics. It is best classified as a botanical natural health product / dietary supplement with immunomodulatory and anti-inflammatory activity rather than as a defined anticancer drug. Its most defensible cancer-relevant identity is an immune-axis modulator with inconsistent direct tumor-cell cytotoxicity depending on species, plant part, extract chemistry, and concentration.
-concentration of cichoric acid used as quality marker.
-best form is: Echinacea purpurea fresh aerial herb expressed juice

Primary mechanisms (ranked):

  1. Innate immune activation through macrophage stimulation, cytokine modulation, and macrophage polarization, especially polysaccharide-driven effects.
  2. NK-cell and Th1-skewing immune support, with possible enhancement of immune surveillance in preclinical models.
  3. CB2-linked alkylamide signaling that can modulate inflammation and, in some cancer-cell models, contribute to apoptosis.
  4. Direct tumor-cell growth inhibition by phenolic-rich extracts or cichoric acid, including telomerase suppression, β-catenin downregulation, caspase-9/PARP activation, and apoptosis in selected in-vitro models.
  5. ROS-associated apoptotic stress in selected cancer-cell models, secondary and formulation-dependent rather than a universal core mechanism.
  6. Context-dependent inflammatory pathway modulation, including NF-κB/MAPK-related signaling, which may support immune activation in normal immune cells but may be undesirable if it supports tumor-promoting inflammation.

Bioavailability / PK relevance: Echinacea is not a single pharmacokinetic entity. Alkylamides are systemically absorbed after oral dosing and can appear in plasma rapidly, whereas higher-molecular-weight polysaccharides are more likely to act through mucosal, gut-associated, or ex-vivo immune interfaces rather than high systemic exposure. Phenolic constituents and cichoric acid have variable exposure and metabolism. Product standardization is a major constraint.

In-vitro vs systemic exposure relevance: Many direct cancer-cell studies use crude extracts or isolated constituents at concentrations that may exceed achievable systemic exposure after oral supplementation. Immune-cell effects may be more plausible at lower exposure or via mucosal immune signaling, but extrapolation to tumor control is uncertain. This is concentration-driven and formulation-driven, not a field-based modality.

Clinical evidence status: Cancer evidence is preclinical / adjunct-risk only. There is no validated human anticancer efficacy signal and no established role as cancer treatment, prevention, radiosensitizer, or chemosensitizer. Human clinical evidence is strongest for short-term upper-respiratory infection indications, not oncology. In cancer patients, the main clinical issue is interaction uncertainty, especially immune therapies, immunosuppressants, CYP3A4/P-gp substrate chemotherapy, allergy risk, and inconsistent supplement composition.


Echinacea Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Macrophage activation and M1 polarization ↓ tumor-supportive immune tolerance (model-dependent) ↑ macrophage activation, ↑ inflammatory cytokine signaling, ↑ tumoricidal phenotype R/G Immune surveillance modulation Most central cancer-relevant mechanism; mainly driven by polysaccharide-rich fractions and immune-cell models.
2 NK cell and Th1 immune surveillance ↓ tumor escape potential (indirect) ↑ NK activity, ↑ MHC II, ↑ Th1-type CD4 response (model-dependent) G Host immune activation Biologically plausible adjunct mechanism, but not validated as clinical anticancer efficacy.
3 CB2 alkylamide signaling ↑ apoptosis in selected models, ↓ viability (context-dependent) ↑ immunomodulation, ↓ excessive TNF-type inflammation (context-dependent) R/G Cannabinoid-receptor-linked immune and death signaling Relevant mainly to alkylamide-rich root preparations; species and extract chemistry strongly affect interpretation.
4 Cichoric acid and phenolic apoptosis axis ↓ proliferation, ↓ telomerase, ↓ β-catenin, ↑ caspase-9, ↑ PARP cleavage ↔ or protective in some nonmalignant models (model-dependent) G Direct cytotoxicity and apoptosis Seen mainly in colon and other cell-line studies; systemic translation is limited by exposure and extract variability.
5 Mitochondrial ROS increase ↑ ROS, ↑ sub-G1 fraction, ↑ caspase-3 activity (model-dependent) ↔ or mixed antioxidant and inflammatory effects R/G Secondary apoptotic stress Not a universal mechanism; appears in selected lung cancer cell models and may depend on extract fraction and concentration.
6 NF-κB and MAPK immune signaling ↔ mixed; possible ↓ survival signaling or ↑ inflammatory support depending on context ↑ immune activation or ↓ excessive inflammation depending on constituent and cell type R/G Context-dependent inflammatory pathway modulation Important but bidirectional. NF-κB activation in immune cells can support host defense, while chronic tumor NF-κB can support cancer progression.
7 Cancer cell proliferation risk ↑ proliferation reported in some cell lines (formulation-dependent) ↔ not clearly harmful in standard short-term use G Potential adverse tumor-context effect Some hydroethanolic preparations promoted growth of HeLa and cholangiocarcinoma-derived QBC-939 cells; this argues against broad anticancer generalization.
8 Clinical Translation Constraint ↔ no proven clinical anticancer efficacy ↑ allergy risk, ↑ interaction uncertainty, possible immune stimulation G Deployment limitation Major constraints are variable species and plant part, inconsistent constituent standardization, uncertain systemic exposure, CYP3A4/P-gp interaction concerns, immune therapy concerns, and lack of oncology RCT efficacy.

P: 0–30 min R: 30 min–3 hr G: >3 hr
IL1β, interleukin-1 beta: Click to Expand ⟱
Source:
Type:
The term "IL-1" is often used as an umbrella term for the interleukin-1 family, which includes multiple cytokines. The two best-known members are IL-1α and IL-1β.
IL-1β is secreted from cells and plays a major systemic role in inflammation. It is a crucial mediator in the inflammatory response and is involved in the fever response, activation of endothelial cells, and leukocyte recruitment.
Its increased expression is commonly linked to:
  – Promotion of a pro-inflammatory microenvironment that supports tumor growth.
  – Enhanced angiogenesis, invasion, and metastasis.
  – Recruitment of myeloid cells that may further suppress antitumor immunity.

High expression of either tends to be associated with a more aggressive phenotype and worse prognosis in many cancer types.
Scientific Papers found: Click to Expand⟱
6626- Cic,  Ech,    Chicoric Acid Ameliorated Beta-Amyloid Pathology and Enhanced Expression of Synaptic-Function-Related Markers via L1CAM in Alzheimer’s Disease Models
- in-vivo, Nor, NA
*antiOx↑, *Obesity↓, *memory↑, *Aβ↓, *MAPK↓, *NF-kB↓, *iNOS↓, *COX2↓, *IL1β↓, *TNF-α↓, *NF-kB↓,
6625- Cic,  Ech,    Chicoric acid supplementation prevents systemic inflammation-induced memory impairment and amyloidogenesis via inhibition of NF-κB
- in-vivo, NA, NA
*memory↑, *Aβ↓, *BACE↓, *MAPK↓, *NF-kB↓, *NF-kB↓, *iNOS↓, *COX2↓, *IL1β↓, *TNF-α↓, *BDNF∅, *MMPs↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 2,   MAPK↓, 2,  

Migration(tgid=13) ⓘ

MMPs↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IL1β↓, 2,   NF-kB↓, 4,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF∅, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   BACE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

memory↑, 2,   Obesity↓, 1,  
Total Targets: 13

Scientific Paper Hit Count for: IL1β, interleukin-1 beta
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:215  Target#:978  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page